Product Information
Registration Status: ActiveSIN13858P
PRISTIQ EXTENDED-RELEASE TABLET 100MG is approved to be sold in Singapore with effective from 2010-08-30. It is marketed by PFIZER PTE LTD, with the registration number of SIN13858P.
This product contains Desvenlafaxine 100mg in the form of TABLET, EXTENDED-RELEASE. It is approved for ORAL use.
This product is manufactured by Wyeth Pharmaceuticals Company in PUERTO RICO, andPfizer Ireland Pharmaceuticals in IRELAND.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin-norepinephrine reuptake inhibitor (SNRI class). Desvenlafaxine may be used to treat major depressive disorder and is being studied for use in the management of vasomotor symptoms in postmenopausal women. It is formulated as an extended release tablet. FDA approved in 2008.
Indication
Desvenlafaxine is indicated for the treatment of major depressive disorder in adults.
Mechanism of Action
Desvenlafaxine, the major active metabolite of venlafaxine, is a selective serotonin and norepinephrine reuptake inhibitor. The clinical effect of desvenlafaxine is thought to occur via potentiation of serotonin and norepinephrine in the central nervous system. Unlike venlafaxine, desvenlafaxine is thought to have a differential serotonergic and noradrenergic activity profile.
Pharmacokinetics
- Absorption
- Absolute bioavailability is approximately 80% and is unaffected by food. Peak plasma concentration is reached in 7.5 hours.
- Distribution
- 3.4 L/kg, distribution into nonvascular compartments
- Metabolism
- The primary route of metabolism is via conjugation mediated by UGT isoforms. Desvenlafaxine also undergoes oxidative N-demethylation via cytochrome P450 3A4 to a minor extent. CYP2D6 is not involved with the metabolism of desvenlafaxine.
- Elimination
Toxicity
The safety and tolerability of desvenlafaxine is similar to other SNRIs. Common side effects upon initiation or dose increase include increased blood pressure and heart rate, agitation, tremor, sweating, nausea, headache, and sleep disturbances. May cause sexual dysfunction and weight loss in some patients. May cause increases in fasting serum total cholesterol, LDL cholesterol, and triglycerides. Withdrawal effects may occur and thus, the dose of desvenlafaxine should be titrated down prior to discontinuation.
Active Ingredient/Synonyms
Desvenlafaxine | O-desmethylvenlafaxine | ODV | Desvenlafaxine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.